April 10, 2022 12:00 PM EDTUpdated April 11, 06:32 AM
R&D
Pharma

AACR22: Am­gen re­veals new long-term da­ta for Lumakras, look­ing to keep press­ing mar­ket ad­van­tage over Mi­rati

Max Gelman

Senior Editor

NEW OR­LEANS — Am­gen at­tempt­ed to fur­ther pull away from Mi­rati Ther­a­peu­tics in the KRAS space, tout­ing a new batch of long-term non-small cell lung can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times